Will Antiangiogenic Agents be a Future for Mesothelioma Therapy?

C. Belli, S. Anand, M. Panella, M. Giovannini, G. Tassi, Dean Fennell, L. Mutti

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Background: Malignant mesothelioma (MM) is an aggressive disease that is diagnosed mostly in locally advanced or metastatic stage. In this condition chemotherapy with the combination cisplatin and pemetrexed or ralitrexed represents the standard treatment as supported by a phase III study. However, chemotherapy has very limited effect on the improvement of survival of patients and very few of the MM patients survive more than 2 years. A better understanding of molecular mechanisms and pathways involved in angiogenesis in MM is the basis for the development of new drugs targeted against these pathways responsible for the proliferation and survival of tumor cells.
Original languageEnglish
Pages (from-to)3069-3079
Number of pages11
JournalCurrent medicinal chemistry
Volume17
Issue number27
Publication statusPublished - 2010

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Will Antiangiogenic Agents be a Future for Mesothelioma Therapy?'. Together they form a unique fingerprint.

Cite this